Literature DB >> 24063059

On the MTD paradigm and optimal control for multi-drug cancer chemotherapy.

Urszula Ledzewicz1, Heinz Schättler, Mostafa Reisi Gahrooi, Siamak Mahmoudian Dehkordi.   

Abstract

In standard chemotherapy protocols, drugs are given at maximum tolerated doses (MTD) with rest periods in between. In this paper, we briey discuss the rationale behind this therapy approach and, using as example multidrug cancer chemotherapy with a cytotoxic and cytostatic agent, show that these types of protocols are optimal in the sense of minimizing a weighted average of the number of tumor cells (taken both at the end of therapy and at intermediate times) and the total dose given if it is assumed that the tumor consists of a homogeneous population of chemotherapeutically sensitive cells. A 2-compartment linear model is used to model the pharmacokinetic equations for the drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24063059     DOI: 10.3934/mbe.2013.10.803

Source DB:  PubMed          Journal:  Math Biosci Eng        ISSN: 1547-1063            Impact factor:   2.080


  4 in total

1.  Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases.

Authors:  Ami B Shah; Katarzyna A Rejniak; Jana L Gevertz
Journal:  Math Biosci Eng       Date:  2016-12-01       Impact factor: 2.080

Review 2.  Computational oncology--mathematical modelling of drug regimens for precision medicine.

Authors:  Dominique Barbolosi; Joseph Ciccolini; Bruno Lacarelle; Fabrice Barlési; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

3.  Dose Titration Algorithm Tuning (DTAT) should supersede 'the' Maximum Tolerated Dose (MTD) in oncology dose-finding trials.

Authors:  David C Norris
Journal:  F1000Res       Date:  2017-02-07

Review 4.  Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities.

Authors:  Angela M Jarrett; Danial Faghihi; David A Hormuth Ii; Ernesto A B F Lima; John Virostko; George Biros; Debra Patt; Thomas E Yankeelov
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.